drugset
Drugs / Peptide vaccine IPX
last change Sep 2023 re-read 3 minutes ago

Peptide vaccine IPX

also known as IPX vaccine

Vaccine

Developed for
Ewing sarcoma · rhabdomyosarcoma · synovial sarcoma
Investigated by
Cooperative Ewing Sarkom Studiengruppe · Cooperative Weichteilsarkom Study Group · Deutsches Konsortium fürTranslationale Krebsforschung (DKTK) · University Hospital Tuebingen

Trials 1

today NCT06094101 · Ph 1/2
2024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT06094101 Sep 2023 → Jun 2027 expected Ewing sarcoma, rhabdomyosarcoma, synovial sarcoma University Hospital Tuebingen Recruiting No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Peptide vaccine IPX ClinicalTrials.gov intervention name — accepted as the source's own label NCT06094101 ↗
Known as IPX vaccine “patient-individualized peptide vaccination (IPX vaccine)” NCT06094101 ↗
Modality Vaccine “personalized peptide vaccine” NCT06094101 ↗
Route Subcutaneous “Peptides will be administered subcutaneously (s.c.)” NCT06094101 ↗